Interview Summary	Application No.	Applicant(s)
	09/581,967	ABRAHAMSSON ET AL.
	Examiner	Art Unit
	Micah-Paul Young	1615
All participants (applicant, applicant's representative, PTO personnel):		
(1) <u>Micah-Paul Young</u> .	(3)	
(2) <u>John Genova</u> .	(4)	
Date of Interview: <u>11 March 2003</u> .		
Type: a)⊠ Telephonic b)□ Video Conference c)□ Personal [copy given to: 1)□ applicant 2)□ applicant's representative]		
Exhibit shown or demonstration conducted: d) Yes e) No. If Yes, brief description:		
Claim(s) discussed: <u>29 and 33</u> .		
Identification of prior art discussed:		
Agreement with respect to the claims f) \boxtimes was reached. g) \square was not reached. h) \square N/A.		
Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Applicant suggested to further limit claims 29 and 33. THe amendments to claim 29 would clear up possible indefiniteness issues. The amendments further limit the IBAT inhibitor and bile acid binder		
to where they are released in the intestinal tract.		
(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)		
THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.		
		•

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Examiner's signature, if required



Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record

A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews

Paragraph (b)

In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

37 CFR §1.2 Business to be transacted in writing.

All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:

- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by
 attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does
 not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case unless both applicant and examiner agree that the examiner will record same. Where the examiner agrees to record the substance of the interview, or when it is adequately recorded on the Form or in an attachment to the Form, the examiner should check the appropriate box at the bottom of the Form which informs the applicant that the submission of a separate record of the substance of the interview as a supplement to the Form is not required.

It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

- A complete and proper recordation of the substance of any interview should include at least the following applicable items:
- 1) A brief description of the nature of any exhibit shown or any demonstration conducted,
- 2) an identification of the claims discussed,
- 3) an identification of the specific prior art discussed,
- 4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
- 5) a brief identification of the general thrust of the principal arguments presented to the examiner,
 - (The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
- 6) a general indication of any other pertinent matters discussed, and
- 7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

Examiner to Check for Accuracy

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.

FROM W&C LLP 19TH FL.

LOS ANGLLES
MIAMI
NEW YORK
PALO ALTO
WASHINGTON, D.C.

BERLIN
BRATISLAVA
BRUSGELS
BUDAPEST
ORESOEN
DÜSSGLOORF
FRANKPURT
HAMBURG
HELSINNI
1STANBUL
LONDON
MILAN
MOSCOW
PARIS
PRAGUE
ROME
STOCKHOLM
WARSAW

(TUE) _3. 11' 03 3:13/ST. 3:13/NO. 4260454716 P 1

WHITE & CASE

1155 AVENUE OF THE AMERICAS NEW YORK, NEW YORK 10036-2787

TELEPHONE: (1-212) 819-8200 FACSIMILE: (1-212) 354-8113

DIRECT DIAL: 212-819-8832

ANKARA BANGKOK BOMBAY/MUMBAI HO CHI MINH CITY HONG KONG JAKARTA SHANGHAI SINGAPORE TOKYO

> BAHRAIN JEDDAH RIYADH

MEXICO CITY SÃO PAULO

JOHANNESBURG

FACSIMILE TRANSMISSION

Date:

11 March 2003

No. of Pages (including cover):

2

To:

Examiner Micah Paul Young

USPTO

Art Unit 1615

Fax Number:

703-746-7648

Contact Number.

From:

John M. Genova

Reference No.:

1103326-0624

Re:

U.S. Patent Appln. Serial. No. 09/581,967

PLEASE NOTE: The information contained in this facsimile message is privileged and confidential, and a intended only for the use of the individual named above and others who have been specifically authorized to receive it. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, or if any problems occur with transmission, please contact sender or call (212) 819-7583. Thank you.

Dear Examiner Young:

As we discussed today, Applicants approve the amendment of claims 29 and 33, as shown on page 2, by Examiner's Amendment.

Thank you for your cooperation in this matter.

Sincerely,

John M. Genova Reg. No. 32,224

(

WHITE & CASE

New York

29. A pharmaceutical formulation [,] comprising therapeutically effective amounts of an IBAT inhibitor compound and a bile acid binder, wherein the IBAT inhibitor compound is formulated for delivery of the IBAT inhibitor compound in the ileum and the bile acid binder is coating layered for targeted release of the bile acid binder in the colon.

Support for the amended claim 29 is provided by the specification at 7, line 11, to page 8, line 5.

33. A pharmaceutical formulation [,] comprising therapeutically effective amounts of an IBAT inhibitor compound and a bile acid binder, wherein the IBAT inhibitor compound [formulation] is coating layered for targeted release of the IBAT inhibitor compound in the ileum and the bile acid binder is coating layered for targeted release of the bile acid binder in the colon.

Support for amended claim 33 is provided by the specification at page 11, lines 25-27.

FACSIMILE TRANSMISSION